渤健Biogen (BIIB) 2018年年度报告「NASDAQ」.pdf

1、Biogen 2018 Annual Report Biogen 2018 Annual Report 2018 ANNUAL REPORTBiogen 2018 Annual Report 2018 ANNUAL REPORTBiogen 2018 Annual Report Biogen2018 Annual Report 021 Non-GAAP diluted earnings per share(EPS)and Free Cash Flow are Non-GAAP financial measures.A reconciliation of GAAP to Non-GAAP dil

2、uted EPS and Free Cash Flow amounts is set forth on pages 1921 of this Annual Report.2 GAAP diluted EPS for 2018 and 2017 includes charges of$125 million and$1,176 million,respectively,related to the impact of the Tax Cuts and Jobs Act of 2017.3 Free Cash Flow for 2018 and 2017 reflects an increase

3、in capital expenditures related to the construction of our large-scale biologics manufacturing facility in Solothurn,Switzerland.HIGHLIGHTSStrong financial performance4 For 2018 and 2017 Other includes product revenues from FAMPYRA,FUMADERM,BENEPALI,FLIXABI and ZINBRYTA.For 2018 Other also includes

4、product revenues from IMRALDI,which was launched in Europe in October 2018.For 2017 Other also includes product revenues from ALPROLIX and ELOCTATE through January 31,2017.No product revenues for ALPROLIX and ELOCTATE were recognized subsequent to February 1,2017,the effective date of the spin-off o

5、f our hemophilia business.5 Interferon includes AVONEX and PLEGRIDY.Free Cash Flow 1,3($inmillions)20142015201620172018$2,279$2,223$2,706$2,484$3,917Strong financial performanceProduct Revenues($inmillions and%of total product revenues)Total Revenues($inmillions)GAAP Diluted EPS/Non-GAAP Diluted EPS

6、 120142015201620172018$9,703$10,764$11,449$12,274$13,45320142015201620172018$13.83$17.01$20.22$12.37$15.34$16.93$11.922$21.582$21.81$26.20TECFIDERA$4,274$4,21439%41%Other4$662$6386%5%Interferon5$2,363$2,64622%26%TYSABRI$1,864$1,97317%19%SPINRAZA$1,724$88416%9%2017201820182017Product Revenues by Regi